Table 4.
Prior Treatments Given to Responders (CR + CRp) in the Current Study
| Frontline Treatment | Response to Frontline Treatment | Cenersen Treatment Group | Response to Cenersen Regimen |
|---|---|---|---|
| Daunorubicin, 60 mg/m2/d, days 1–3 Cytarabine, 200 mg/m2/d, days 1–7 PKC 412, 200 mg/d, days 8–31 |
Refractory | 1 | CRp |
| Daunorubicin, 60 mg/m2/d, days 1–3 Cytarabine, 200 mg/m2/d, days 1–7 PKC 412, 200 mg/d, days 1–31 |
Refractory | 1 | CR |
| Idarubicin, 12 mg/m2/d, days 1–3 Cytarabine, 1.5 g/m2/d, days 1–4 Then as consolidation: Cytarabine, 100 mg/m2/d × 5 days Idarubicin, 8 mg/m2/d + Cytarabine, 1.5 g/m2/d × 2 days Cytarabine, 100 mg/m2/d × 5 days |
Relapse | 2 | CR |
| Daunorubicin (20mg/m2/d × 4d) ×2 Cytarabine (200mg/m2/d × 4d) ×2 Etoposide (100mg/m2/d ×4d) ×2 Thioguanine (100mg/m2/d ×4d) ×2 Dexamethasone (6mg/m2/d ×4d) ×2 Cytarabine intrathecal (70mg) ×2 |
Relapse | 2 | CRp |
| Idarubicin, 12 mg/m2/d, days 4–6 Cytarabine, 1.5 g/m2/d, days 4–7 |
Refractory | 3 | CR |
| Daunorubicin, 45 mg/m2/d, days 1–3 Cytarabine, 100 mg/m2/d, days 1–8 Zosuquidar, 700 mg/d, days 1–3 |
Refractory | 3 | CR |
| Daunorubicin* × 3 days Cytarabine* × 7days |
Refractory | 3 | CR |
| Idarubicin, 12 mg/m2/d × 3 days Cytarabine, 100 mg/m2/d, × 7 days |
Refractory | 2 | CR |
| Daunorubicin, 90 mg/m2/d, days 1–3 Cytarabine, 100 mg/m2/d, days 1–7 Etoposide, 100 mg/m2/d, days 1–3 Then as consolidation: HIDAC × 3 courses |
Relapsed | 2 | CR |
| Idarubicin* Cytarabine* Etoposide* Then as consolidation: HIDAC* |
Relapsed | 3 | CR |
*
Dose unknown
HIDAC = high dose Ara-C
CR indicates complete response
CRp indicates complete response with incomplete platelet recovery